Cervical LesionNCT04735718
Clinical Investigation To Evaluate Cerviron Ovules® in Cervix Lesions Postoperative Care
A study testing Cerviron in people with Cervical Lesion, run by Perfect Care Distribution at 3 sites in Romania.
Trial summary
CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron® Ovules in Cervix Lesions Postoperative Care. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in postoperative care in patients that… Read more about this study
- Who is it for?
- Ages 18 to 65 years, women only
- Conditions the study is for
- Cervical Lesion
- What is being tested?
- Cerviron
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 3 sitesRomania
- Study dates
- 1 Aug 2021to 16 Jan 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult females, aged 18 years to 65 years;
- Subjects presenting benign, ectopic, cervix lesions that were excised no later than 7 days before the Screening Visit, confirmed by colposcopy;
- Subjects presenting a normal cervical cytology report, e.g. Negative for Intraepithelial Lesions or Malignancy (NILM) or slightly modified to Atypical Squamous Cells of Undetermined Significance (ASC-US) in the last 6 months;
- Subjects willing to provide signed informed consent to clinical investigation participation.
Who cannot join
- Previous history of any malignancy, particularly those that are prone to metastases, including breast, melanoma, gestational trophoblastic disease, and high-grade malignancies of the gastrointestinal tract or lung;
- Subjects with undiagnosed abnormal genital bleeding;
- Subject with vulvar, vaginal or cervical cancer;
- Subjects presenting an abnormal cytology report, e.g. cervical intraepithelial neoplasia" (CIN) or "adenocarcinoma in situ" (AIS) in the last 6 months;
- Watery or foul discharge;
- Subjects with HIV or other immunodeficiency;
Show all 11Show fewer
- Use of spermicides;
- Use of diaphragm;
- Concomitant topical or systemic anti-infective treatment;
- Unable to comply with visit procedures;
- Subjects included in other clinical investigations with similar objectives
Trial locations and contacts
3 sites in 1 country.
Romania3 sites
Institutul National pentru Sanatatea Mamei si Copilului " Alessandrescu-Rusescu"
Bucharest
Centrul Medical MIȘCĂ
Timișoara
Spitalul Clinic Județean de Urgență "Pius Brinzeu"
Timișoara
About this study
Official title: A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron® Ovules in Cervix Lesions Postoperative Care
CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron® Ovules in Cervix Lesions Postoperative Care. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in postoperative care in patients that underwent surgical removal of benign, cervical lesions. The secondary objective of this clinical investigation is the assessment of performance of the medical device by clinical exam and patients' degree of satisfaction related to the use of the medical device.
Read the detailed description
Identifying premalignant and benign diseases of the cervix and selecting an appropriate treatment path can be challenging. The adult uterine cervix may exhibit a wide variety of pathologic conditions that include benign entities (eg, cervicitis, hyperplasia, nabothian cysts, cervical polyps, leiomyomas, endometriosis, and congenital abnormalities) as well as malignant lesions, particularly cervical carcinoma.
Cervical lesions range from being visible only with an instrument that augments sight such as a colposcope to being visible by speculum examination or endovaginal ultrasound.
The most frequent types of cervical lesions are:
- Cervical polyp Cervical polyps are benign growths, usually protruding from the surface of the cervical canal. They commonly occur during the reproductive years, especially in women over 20 years of age. Cervical polyps are the most common non-cancerous tumour of the cervix.
The cervical polyps may vary in size, shape, and origin. They can present as single or multiple, tear-shaped or lobular, cherry-red, or greyish-white in color, depending on the vascularity of the lesion. The size of the cervical polyp is typically less than three cm in diameter; however, as mentioned earlier, they can vary in size and can be large enough to fill the vagina or be present at the introitus They usually originate in the endocervical canal. Endocervical polyps may be caused by chronic inflammation. They rarely become malignant.
Nabothian cyst Nabothian cysts are a benign gynecological condition in reproductive age without clinical significance. These cysts are at the squamocolumnar junction of the uterine cervix, which is the targeted anatomical area of brush sampling at the time of cervical screening cytology. They are filled with mucus, but they may also contain proteinaceous material, neutrophils, or neutrophil debris. These cysts usually appear superficially and are easily recognized during colposcopy examination. If left untreated, they can induce considerable enlargement of the cervix, which can lead to symptomatology. Other causes of these large cysts include cystic degeneration of uterine leiomyoma and congenital uterine cysts such as mesonephric and paramesonephric cysts and cystic adenomyosis.
Complications of Nabothian cysts include hematometra, labor passage obstruction, rectal compression, abnormal uterine bleeding, specifically in case of giant cysts, and chronic urinary retention by restricting the bladder's outlet or by compressing the pudendal and sacral nerves, thus, disturbing the nerve supply to the detrusor muscle.
Cervical fibroid Cervical fibroids (myomas) start in the muscle tissue of the cervix. They are similar to uterine fibroids but less common. Cervical fibroids may not cause symptoms. The most common symptom is abnormal vaginal bleeding. Pain during intercourse may happen. If the fibroid becomes large, it may partially block the urinary tract and cause urinary drainage problems such as dribbling or urinary retention. If myomas become infected, they may cause pain, bleeding, or a discharge from the vagina.
The recommended treatment in all cases is excision. After surgery, haemostasis and rapid recovery should be promoted with the support of local, re-epithelizing treatments.
Cerviron® ovules Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
Bismuth subgallate causes shrinkage of damaged tissue by stopping bleeding and promoting tissue healing. Being an insoluble salt and very little absorbed the bismuth subgalate forms a protective film that allows the other components to act locally. "Through its active ingredient, Bismuth subgallate, Cerviron® ovules exert a protective action on mucous membranes and raw surfaces. Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations.
The Marigold extract (Calendula Officinalis) contains as active principles carotenoid substances, triterpenic compounds and volatile oil, favouring a healing, antitricomonazic effect and reducing the excessive secretion (leucorrhea). Flavonoids and triterpene glycosides boast soothing properties and also help improve microcirculation. Marigold is mainly used for treating skin disorders: irritation, redness and inflammation. The plant was employed in the civil war to treat wounds.
This is the second clinical investigation on human subjects with this medical device, in which 50 patients will be enlisted, and which will take place in two research centres in Romania.
- Conditions
- Cervical Lesion
- Being tested
- Cerviron
- Keywords
- cervical lesion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CervironDevice
Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations.
| Study group | Role | What they receive |
|---|---|---|
| Cerviron vaginal ovules | Experimental | Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation. The main objectives and clinical endpoints are the performance and the safety profile of the investigational device. Receives: Device: Cerviron |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Performance Assessed by the Investigator by Colposcopy at End of Treatment Visit
Evolution of cervical lesions at End of Treatment Visit
Measured: 3 months
Rate of treatment-related Adverse Events in subjects participating in the clinical investigation
Number and degree of AE
Measured: 3 months
Secondary outcomes (3)
The Re-epithelialization degree of the cervical mucosa by thorough gynaecological examination (visual evaluation)
Gynecological examination by speculum at 1, 2 and 3 months
Measured: at 1, 2 and 3 months
Evolution of vaginal symptoms and discomfort
Presence/absence of symptoms such as pain and/or bleeding at 1, 2 and 3 months
Measured: at 1, 2 and 3 months
Patient Satisfaction (Likert Scale)
5 point Likert scale to evaluate the degree of satisfaction after the treatment
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2021
- Study start1 Aug 2021
- Primary completion6 Jan 2023
- Study completion16 Jan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cervical LesionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation
- Masking
- None (open label)
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- Perfect Care Distribution
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- MDX Research
- Responsible party
- Sponsor
- Investigators
- Ramona Petrita, CSO, Study director, MDX Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04735718
- Sponsor's protocol ID
- CYRON/02/2021
- Status last verified
- Jan 2023
- First submitted
- 29 Jan 2021
- Last updated
- 20 Jan 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Petre I, Toader DO, Petrita R, Pinta AR, Alexa AA, Bita RG. Clinical Performance and Safety of Cerviron(R) Vaginal Ovules in the Management of Symptomatic Cervical Lesions: A National, Multicentric Study. Curr Ther Res Clin Exp. 2024 Oct 9;101:100762. doi: 10.1016/j.curtheres.2024.100762. eCollection 2024.
PubMed 39717511
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron® Ovules in Cervix Lesions Postoperative Care
- ClinicalTrials.gov ID
- NCT04735718
- Acronym / sponsor ID
- CYRON/02/2021
- Conditions
- Cervical Lesion
- Keywords
- cervical lesion
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- Perfect Care DistributionIndustry (pharma, biotech, devices)
- Collaborators
- MDX Research
- Study start
- 1 Aug 2021 (actual)
- Primary completion
- 6 Jan 2023 (actual)
- Study completion
- 16 Jan 2023 (actual)
- First posted
- 3 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron® Ovules in Cervix Lesions Postoperative Care. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in postoperative care in patients that underwent surgical removal of benign, cervical lesions. The secondary objective of this clinical investigation is the assessment of performance of the medical device by clinical exam and patients' degree of satisfaction related to the use of the medical device.
Detailed description
Identifying premalignant and benign diseases of the cervix and selecting an appropriate treatment path can be challenging. The adult uterine cervix may exhibit a wide variety of pathologic conditions that include benign entities (eg, cervicitis, hyperplasia, nabothian cysts, cervical polyps, leiomyomas, endometriosis, and congenital abnormalities) as well as malignant lesions, particularly cervical carcinoma.
Cervical lesions range from being visible only with an instrument that augments sight such as a colposcope to being visible by speculum examination or endovaginal ultrasound.
The most frequent types of cervical lesions are:
- Cervical polyp Cervical polyps are benign growths, usually protruding from the surface of the cervical canal. They commonly occur during the reproductive years, especially in women over 20 years of age. Cervical polyps are the most common non-cancerous tumour of the cervix.
The cervical polyps may vary in size, shape, and origin. They can present as single or multiple, tear-shaped or lobular, cherry-red, or greyish-white in color, depending on the vascularity of the lesion. The size of the cervical polyp is typically less than three cm in diameter; however, as mentioned earlier, they can vary in size and can be large enough to fill the vagina or be present at the introitus They usually originate in the endocervical canal. Endocervical polyps may be caused by chronic inflammation. They rarely become malignant.
Nabothian cyst Nabothian cysts are a benign gynecological condition in reproductive age without clinical significance. These cysts are at the squamocolumnar junction of the uterine cervix, which is the targeted anatomical area of brush sampling at the time of cervical screening cytology. They are filled with mucus, but they may also contain proteinaceous material, neutrophils, or neutrophil debris. These cysts usually appear superficially and are easily recognized during colposcopy examination. If left untreated, they can induce considerable enlargement of the cervix, which can lead to symptomatology. Other causes of these large cysts include cystic degeneration of uterine leiomyoma and congenital uterine cysts such as mesonephric and paramesonephric cysts and cystic adenomyosis.
Complications of Nabothian cysts include hematometra, labor passage obstruction, rectal compression, abnormal uterine bleeding, specifically in case of giant cysts, and chronic urinary retention by restricting the bladder's outlet or by compressing the pudendal and sacral nerves, thus, disturbing the nerve supply to the detrusor muscle.
Cervical fibroid Cervical fibroids (myomas) start in the muscle tissue of the cervix. They are similar to uterine fibroids but less common. Cervical fibroids may not cause symptoms. The most common symptom is abnormal vaginal bleeding. Pain during intercourse may happen. If the fibroid becomes large, it may partially block the urinary tract and cause urinary drainage problems such as dribbling or urinary retention. If myomas become infected, they may cause pain, bleeding, or a discharge from the vagina.
The recommended treatment in all cases is excision. After surgery, haemostasis and rapid recovery should be promoted with the support of local, re-epithelizing treatments.
Cerviron® ovules Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
Bismuth subgallate causes shrinkage of damaged tissue by stopping bleeding and promoting tissue healing. Being an insoluble salt and very little absorbed the bismuth subgalate forms a protective film that allows the other components to act locally. "Through its active ingredient, Bismuth subgallate, Cerviron® ovules exert a protective action on mucous membranes and raw surfaces. Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations.
The Marigold extract (Calendula Officinalis) contains as active principles carotenoid substances, triterpenic compounds and volatile oil, favouring a healing, antitricomonazic effect and reducing the excessive secretion (leucorrhea). Flavonoids and triterpene glycosides boast soothing properties and also help improve microcirculation. Marigold is mainly used for treating skin disorders: irritation, redness and inflammation. The plant was employed in the civil war to treat wounds.
This is the second clinical investigation on human subjects with this medical device, in which 50 patients will be enlisted, and which will take place in two research centres in Romania.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation
| Arm | Type | Receives |
|---|---|---|
| Cerviron vaginal ovules | Experimental | Device: CervironSince Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation. The main objectives and clinical endpoints are the performance and the safety profile of the investigational device. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult females, aged 18 years to 65 years;
- Subjects presenting benign, ectopic, cervix lesions that were excised no later than 7 days before the Screening Visit, confirmed by colposcopy;
- Subjects presenting a normal cervical cytology report, e.g. Negative for Intraepithelial Lesions or Malignancy (NILM) or slightly modified to Atypical Squamous Cells of Undetermined Significance (ASC-US) in the last 6 months;
- Subjects willing to provide signed informed consent to clinical investigation participation.
Key exclusion criteria (11 listed)
- Previous history of any malignancy, particularly those that are prone to metastases, including breast, melanoma, gestational trophoblastic disease, and high-grade malignancies of the gastrointestinal tract or lung;
- Subjects with undiagnosed abnormal genital bleeding;
- Subject with vulvar, vaginal or cervical cancer;
- Subjects presenting an abnormal cytology report, e.g. cervical intraepithelial neoplasia" (CIN) or "adenocarcinoma in situ" (AIS) in the last 6 months;
- Watery or foul discharge;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CervironCerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens. Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations. | Device | Cerviron vaginal ovules |
Primary outcome
Clinical Performance Assessed by the Investigator by Colposcopy at End of Treatment Visit
Time frame: 3 months
Evolution of cervical lesions at End of Treatment Visit
Rate of treatment-related Adverse Events in subjects participating in the clinical investigation
Time frame: 3 months
Number and degree of AE
3 secondary outcomes
The Re-epithelialization degree of the cervical mucosa by thorough gynaecological examination (visual evaluation)
Time frame: at 1, 2 and 3 months
Evolution of vaginal symptoms and discomfort
Time frame: at 1, 2 and 3 months
Patient Satisfaction (Likert Scale)
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2023.
- Derived from this study: PubMed 39717511Petre I, Toader DO, Petrita R, Pinta AR, Alexa AA, Bita RG. Clinical Performance and Safety of Cerviron(R) Vaginal Ovules in the Management of Symptomatic Cervical Lesions: A National, Multicentric Study. Curr Ther Res Clin Exp. 2024 Oct 9;101:100762. doi: 10.1016/j.curtheres.2024.100762. eCollection 2024.
- Individual participant dataSharing planned: No
Related trials for Cervical Lesion
RecruitingObservational study
Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
Esophageal Neoplasm, Esophageal Polyp
RecruitingPhase 3
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm
Not yet recruitingObservational study
Clinical Audit of Cervical Cytology Services in an Early Cancer Detection Unit
Cervical Intraepithelial Neoplasia, Uterine Cervical Neoplasms
Active, not recruitingObservational study
Comparison of TLC (Total Leucocyte Count), Neutrophils and Monocytes in Oral Squamous Cell Carcinoma and Pre-malignant Disorders
Oral Squamous Cell Carcinoma (OSCC), Premalignant Lesion
Active, not recruitingObservational study
Predictive Biomarkers for Precision Management of Pre-cancerous Cervical Neoplasia
HSIL, High Grade Squamous Intraepithelial Lesion, DNA Methylation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ramona Petrita, CSO study director
MDX Research
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cerviron in people with Cervical Lesion, run by Perfect Care Distribution at 3 sites in Romania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Performance Assessed by the Investigator by Colposcopy at End of Treatment Visit (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04735718, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2023.